Transdermals

Estradiol Topical

Updated · 19 sources · Editorial policy

Topical (transdermal) estradiol is plain 17β-estradiol, the main human estrogen, delivered through the skin from a patch, gel or spray instead of being swallowed or injected. In the US it is sold as weekly or twice-weekly patches (Climara, Vivelle-Dot, Menostar and generics), daily gels (EstroGel, Divigel) and a daily spray (Evamist). The labels cover menopausal hot flashes, vaginal atrophy, low estrogen from hypogonadism or ovarian failure, and prevention of postmenopausal osteoporosis, depending on the product.

The most important fact is that skin delivery skips first-pass metabolism in the liver. The Climara label notes that systemic availability is about 20 times higher than with oral dosing. Large observational studies link the transdermal route to little or no increase in blood clot risk, unlike oral estrogen. Those studies were not randomized, though, and every US label still carries a boxed warning. In February 2026 the FDA approved the first labels that removed the cardiovascular, breast cancer and dementia statements from that warning.

This page summarizes what the FDA labels, observational studies and randomized trials report. It is for education only and is not medical advice.

Property Detail
Drug class Estrogen (17β-estradiol, no ester)
US products Patches: Climara, Vivelle-Dot, Menostar; gels: EstroGel 0.06%, Divigel 0.1%; spray: Evamist
Route Transdermal: patch on abdomen or buttock; gel on arm or thigh; spray on inner forearm
Labeled strengths Patches 0.014–0.1 mg/day; gels 0.25–1.25 mg estradiol/day (Divigel) or 0.75 mg/day (EstroGel); spray 1.53 mg per spray, 1–3 sprays/day
Half-life (labels) ≈36 h after EstroGel; ≈10 h after Divigel; 5.9–7.7 h after Vivelle-Dot. Patch levels return to baseline within 24 h of removal
Key kinetic fact No first-pass liver metabolism; Climara 0.1 mg/day gives average estradiol ≈80–106 pg/mL
Boxed warning Endometrial cancer in women with a uterus (all labels); older labels also list cardiovascular disease, breast cancer and dementia
US status Prescription only; not a controlled substance
WADA status Not on the 2026 Prohibited List (aromatase inhibitors and anti-estrogens are, under S4)

What it is

Estradiol is estra-1,3,5(10)-triene-3,17β-diol, formula C₁₈H₂₄O₂, molecular weight 272.39 g/mol (Divigel label). Topical products contain the free hormone, not an ester. There is nothing to cleave off, so a “0.05 mg/day” patch means 0.05 mg of estradiol per day reaching the body.

Estradiol acts on two nuclear estrogen receptors whose share varies by tissue. It also lowers LH and FSH, the pituitary hormones that drive the ovaries and testes, through negative feedback (Climara label). That feedback is why transdermal estradiol can suppress testosterone in men (see below).

The products differ in vehicle, wear time and dose, not in the hormone:

Product Form Labeled dosing Labeled indications
Climara Matrix patch, 6.5–25 cm² 0.025–0.1 mg/day, one patch weekly; start at 0.025 mg/day Hot flashes; vulvar and vaginal atrophy; hypoestrogenism from hypogonadism, castration or primary ovarian failure; osteoporosis prevention
Vivelle-Dot Matrix patch, 2.5–10 cm² 0.025–0.1 mg/day, twice weekly; start at 0.0375 mg/day (0.025 mg/day for bone) Same four as Climara
Menostar Matrix patch, 3.25 cm² 14 mcg/day, one patch weekly Osteoporosis prevention only
EstroGel 0.06% Hydroalcoholic gel, metered pump 1.25 g gel (0.75 mg estradiol) daily, wrist to shoulder on one arm Hot flashes; vulvar and vaginal atrophy
Divigel 0.1% Gel in single-dose packets 0.25–1.25 g gel (0.25–1.25 mg estradiol) daily on the upper thigh Hot flashes
Evamist 1.7% spray, metered pump 1 spray daily to the inner forearm, up to 3 Hot flashes

When vaginal atrophy is the only problem, the EstroGel and Climara labels say to consider vaginal estrogen products first. Those low-dose local products are a different category and are not covered here. Injected estradiol has its own pages: estradiol valerate and estradiol cypionate.

Pharmacokinetics

Estradiol crosses the skin by passive diffusion. The outer skin layer (stratum corneum) is the rate-limiting step. Once absorbed, it is distributed, bound to SHBG and albumin, and metabolized like the body’s own estradiol. The liver converts it reversibly to estrone, partly via CYP3A4, and it is excreted in urine as conjugates (EstroGel label).

Because absorbed estradiol reaches the general circulation before passing through the liver, much less of each dose is lost. The Climara label puts systemic availability at about 20 times that of oral estradiol. Divigel produces estradiol-to-estrone ratios of 0.42–0.65 at steady state (Divigel label). The labels state that the clinical significance of avoiding first-pass metabolism “has not been determined.”

Label data in postmenopausal women:

Product and dose Study Estradiol levels Notes
Climara 0.025 mg/day Single dose, n = 24 Peak 32, average 22 pg/mL Abdomen
Climara 0.1 mg/day Single dose, abdomen n = 139; buttock n = 38 Average 87 pg/mL (abdomen), 106 pg/mL (buttock) Peak and average 25% and 17% higher on the buttock
Climara 0.1 mg/day 3 weekly patches, n = 24 Peak ≈100, trough ≈35 pg/mL Nearly identical curves each week; little or no accumulation
Vivelle 0.0375 and 0.1 mg/day 3 applications, n = 17 25 and 79 pg/mL above baseline Above baseline within 4 h; back to baseline within 24 h of removal
EstroGel 1.25 g (0.75 mg) Daily for 14 days, n = 24 Peak 46.4, average 28.3 pg/mL Half-life ≈36 h
Evamist 1, 2 or 3 sprays Daily for 14 days, n = 72 Average 19.6, 30.7, 30.9 pg/mL Steady state after 7–8 days
Divigel 0.25–1.25 g Daily for 14 days Roughly dose-proportional Steady state by day 12; half-life ≈10 h

Two features stand out. Variability between people is large: the Climara label reports a relative standard deviation of about 50% for kinetic parameters on the abdomen. And the half-lives listed above describe how fast levels fall after a patch is removed or a gel dose wears off, not a fixed property of estradiol.

What changes absorption from gels and sprays

  • Washing: washing the site 1 hour after application cut 24-hour exposure by 22% for EstroGel and by 30–38% for Divigel.
  • Moisturizer and sunscreen: with a 0.06% gel, moisturizer applied 1 hour later raised exposure (AUC) by 38% and peak levels by 73%, while sunscreen lowered both by 16% (EstroGel label).
  • Alcohol base: gels such as Divigel (56% alcohol) are flammable until dry.

Approved medical use

All products are approved for women, mostly after menopause. The Climara and Vivelle-Dot labels also cover hypoestrogenism from hypogonadism, castration or primary ovarian failure. The labels say:

  • Women with a uterus should generally also take a progestogen to lower the risk of endometrial cancer. Women without a uterus generally do not need one.
  • Use the lowest effective dose for the shortest time consistent with treatment goals, and reassess periodically.
  • Dose adjustments follow the clinical response. The Divigel label adds that serum FSH and estradiol levels are not useful for managing hot flashes.

The February 2026 Divigel label adds a timing statement: consider starting it in women under 60 or within 10 years of menopause onset (Divigel label).

What the research shows

Hot flashes and bone in the label trials

The labels report the following placebo-controlled trials:

Product Trial Result
Divigel 0.25, 0.5, 1.0 g/day 12 weeks, 495 postmenopausal women with at least 50 moderate to severe hot flashes/week Frequency and severity fell significantly at week 4 for 0.5 and 1.0 g; at week 7 for 0.25 g; all doses significant at week 12
EstroGel 1.25 g/day 12 weeks, 145 women Significant fall in frequency and severity at weeks 4 and 12
Menostar 14 mcg/day 2 years, 417 women aged 60–80 with a uterus, all on calcium and vitamin D Lumbar spine BMD +2.3% at 1 year and +3.0% at 2 years vs +0.5% on placebo; hip +0.84% vs −0.71% at 2 years (p under 0.001)

Blood clots: oral vs transdermal

Oral estrogen raises the risk of venous thromboembolism (VTE, clots in the leg veins or lungs). Whether skin delivery avoids that risk has been studied only observationally:

Study Design Clot (VTE) risk with transdermal estrogen Comparison with oral
ESTHER (Canonico et al., Circulation 2007) French case-control; 271 cases, 610 controls, ages 45–70 OR 0.9 (95% CI 0.4–2.1) Oral OR 4.2 (95% CI 1.5–11.6)
Meta-analysis (Canonico et al., BMJ 2008) 8 observational studies, 9 RCTs OR 1.2 (95% CI 0.9–1.7) in observational data Oral OR 2.5 (95% CI 1.9–3.4); highest in the first year
QResearch and CPRD (Vinogradova et al., BMJ 2019) UK nested case-control; 80,396 cases, 391,494 controls OR 0.93 (95% CI 0.87–1.01) Oral OR 1.58 (95% CI 1.52–1.64)

ESTHER also found that the type of progestogen mattered: norpregnane derivatives were linked to about 4 times the VTE risk, while micronized progesterone was not. No randomized trial has been large enough to compare clot rates between routes directly.

Stroke

A UK case-control study of 15,710 strokes in women aged 50–79 found no raised risk with transdermal HRT overall (rate ratio 0.95, 95% CI 0.75–1.20) (Renoux et al., BMJ 2010). The results differed by patch dose:

  • low-estrogen-dose patches: rate ratio 0.81 (95% CI 0.62–1.05);
  • high-dose patches: rate ratio 1.89 (95% CI 1.15–3.11);
  • oral HRT, for comparison: rate ratio 1.28 (95% CI 1.15–1.42).

The authors noted that residual confounding could not be ruled out.

Atherosclerosis: the KEEPS trial

KEEPS randomized 727 healthy women aged 42–58, within 6–36 months of their last period, to oral conjugated estrogens 0.45 mg/day, transdermal estradiol 50 mcg/day (each with cyclic oral progesterone), or placebo for 4 years (Harman et al., Ann Intern Med 2014). Results:

  • Carotid wall thickening (the primary endpoint) progressed at the same rate, about 0.007 mm/year, in all three groups.
  • Coronary calcium changes did not differ, and neither drug changed blood pressure.
  • Oral estrogen improved LDL and HDL but raised C-reactive protein and SHBG. Transdermal estradiol lowered insulin resistance.
  • The trial was not powered for heart attacks or strokes.

Men: transdermal estradiol for prostate cancer

The UK PATCH and STAMPEDE trials tested high-dose estradiol patches (100 mcg/24 h patches, several worn at once) as an alternative to LHRH agonists, the standard drugs used to shut down testosterone in prostate cancer. The rationale is that estrogen feedback suppresses testosterone, while skin delivery bypasses first-pass liver metabolism and should avoid the cardiovascular toxicity seen with oral estrogen (Langley et al., Lancet 2021).

Report n Main finding
Langley et al., Eur Urol 2016 74 (bone substudy) Lumbar spine BMD +6.0% at 1 year on patches vs −1.4% on LHRH agonists
Langley et al., Lancet 2021 1694 No difference in time to first cardiovascular event (HR 1.11, 95% CI 0.80–1.53); castration at 3 months 93% in both arms
Langley et al., NEJM 2026 1360, locally advanced cancer 3-year metastasis-free survival 87.1% vs 85.9% (HR 0.96), meeting noninferiority; 5-year overall survival 81.1% vs 79.2% (HR 0.90, 95% CI 0.75–1.07)

The side-effect trade-off was consistent. In the 2026 trial, hot flashes affected 44% on patches vs 89% on LHRH agonists, while gynecomastia (breast growth) affected 85% vs 42%. This use is not on any US label.

Gender-affirming hormone therapy (off-label)

The Endocrine Society guideline lists transdermal estradiol patches at 0.025–0.2 mg/day, with a new patch every 3–5 days, as one option for transgender women. It recommends keeping serum estradiol no higher than 100–200 pg/mL and testosterone under 50 ng/dL, checked every 3 months (Hembree et al., JCEM 2017). This use is not on the US labels.

Side effects and risks

Boxed warning

Every US topical estradiol label reviewed here carries a boxed warning. Its content now depends on the label version:

  • Older labels (Climara, Vivelle-Dot, Menostar, EstroGel and Evamist versions on DailyMed in 2026): endometrial cancer, cardiovascular disorders, probable dementia and breast cancer.
  • Updated labels: on February 12, 2026 the FDA approved the first six revised menopausal hormone therapy labels, removing the cardiovascular, breast cancer and probable dementia statements from the boxed warning (FDA, 2026). The February 2026 Divigel label keeps only “endometrial cancer with unopposed estrogen in women with a uterus” in the box. The cardiovascular and cancer risks remain in its Warnings and Precautions section.

The removed statements came from the Women’s Health Initiative, which tested oral conjugated estrogens, not transdermal estradiol. The labels say the relevance of those findings to “other routes of administration” is not known. Selected results from the WHI estrogen-alone trial (10,739 women, 7.1 years), as reported on the Divigel label:

Event All ages 50–79, RR (95% CI) Ages 50–59, RR (95% CI)
Stroke 1.35 (1.07–1.70) 0.99 (0.53–1.85)
Deep vein thrombosis 1.48 (1.06–2.07) 1.66 (0.75–3.67)
Invasive breast cancer 0.79 (0.61–1.02) 0.82 (0.50–1.34)
Hip fracture 0.67 (0.46–0.96) 5.01 (0.59–42.91)

Endometrial and other cancers

  • Endometrial cancer: with unopposed estrogen in women with a uterus, the risk is 2–12 times that of non-users, and 15–24 times with use for 5–10 years or more. It persists for at least 8–15 years after stopping. A progestogen lowers the rate of endometrial hyperplasia.
  • Breast cancer: a large meta-analysis cited on the Divigel label found RR 1.33 (95% CI 1.28–1.38) for current estrogen-only use lasting 5–14 years, even though WHI estrogen alone showed no increase.
  • Ovarian cancer: RR 1.37 (95% CI 1.26–1.50) for current estrogen-only use in a meta-analysis cited on the same label.

Transfer to other people from gels and sprays

Unlike patches, gels and sprays leave estradiol on the skin, and it can rub off on others:

  • Evamist has a boxed warning for this. Postmarketing reports describe breast budding and breast masses in prepubertal girls, and gynecomastia in prepubertal boys, after contact with a user’s skin. Most cases resolved once exposure stopped. The label also warns that pets, especially small ones, can be harmed (Evamist label).
  • In label transfer studies, 5 minutes of forearm contact 1 hour after Evamist raised a male partner’s estradiol exposure by 4%. Divigel transfer to men was described as “inconclusive.” EstroGel showed no change in female contacts after 15 minutes of contact 1 hour after application.
  • The labels advise letting the product dry, covering the site with clothing, and washing hands.

Common and skin side effects

  • Climara pooled trials (614 women, 3 months): headache 5–18%, edema 0.5–13%, abdominal pain 0–16% across doses, vs 10%, 6% and 8% on placebo. The label lists breast pain, upper respiratory infections, headache, abdominal pain, pain and edema as most common (10% or more).
  • Vivelle-Dot: application-site redness and irritation in 3.2% or fewer of patients.
  • Divigel: application-site reactions in under 1%; the most common reactions above placebo (over 5%) were irregular bleeding, breast tenderness, vaginal yeast infection, nasopharyngitis and upper respiratory infection.

Other risks on the labels

  • Gallbladder disease requiring surgery, increased 2- to 4-fold in postmenopausal women.
  • Severe hypercalcemia in women with breast cancer and bone metastases.
  • Retinal vascular thrombosis; pancreatitis in women with high triglycerides; fluid retention.
  • Higher thyroid-binding globulin, so women on thyroid hormone may need a higher dose.
  • Worsening of hereditary angioedema, asthma, diabetes, epilepsy, migraine, porphyria and lupus.

Drug interactions

Estradiol is partly metabolized by CYP3A4. Inducers such as St. John’s wort, phenobarbital, carbamazepine and rifampin may lower estrogen levels. Inhibitors such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may raise them (Divigel label).

Who should not use it

The February 2026 Divigel label lists:

  • abnormal genital bleeding of unknown cause;
  • current or past breast cancer, or other estrogen-dependent cancer;
  • active or past deep vein thrombosis, pulmonary embolism, stroke or heart attack;
  • liver impairment or disease;
  • protein C, protein S or antithrombin deficiency, or other known clotting disorders;
  • known anaphylaxis, angioedema or hypersensitivity to the product.

The labels advise stopping at once if a clot or stroke occurs and, if feasible, 4–6 weeks before surgery with a high clot risk.

Regulatory status and supply

  • US: prescription-only estrogen. Estradiol is not among the substances named in Schedule III (21 CFR 1308.13).
  • Labels in transition: at the FDA’s request, 29 companies submitted revised menopausal hormone therapy labeling; the six approved in February 2026 were the first batch (FDA, 2026).
  • Supply: in an update current as of September 2026, the FDA reported that some patients had trouble getting their usual estradiol patches after demand rose. Supply had “nearly doubled” over the previous year, and the FDA was working with all six manufacturers (FDA patch availability update).
  • Sport: estradiol is not on the WADA 2026 Prohibited List. Aromatase inhibitors (S4.1) and anti-estrogens and SERMs (S4.2) are prohibited.

Key takeaways

  • Same hormone, different route. Patches, gels and sprays deliver unesterified estradiol through the skin and skip first-pass liver metabolism.
  • Short-lived once removed. Patch levels fall to baseline within 24 hours of removal. Label half-lives range from about 6–8 hours (Vivelle-Dot) to about 36 hours (EstroGel).
  • Lower clot signal, but not from randomized trials. Large case-control studies found no clear rise in VTE with transdermal estrogen (OR 0.9–1.2), compared with OR 1.6–4.2 for oral.
  • Boxed warning is changing. Since February 2026, updated labels keep only the endometrial cancer warning in the box. Women with a uterus generally still need a progestogen.
  • Gels and sprays can transfer. Children exposed to a user’s Evamist-treated skin have developed breast changes; patches avoid this.
  • Also used in men. In prostate cancer, high-dose patches matched LHRH agonists for metastasis-free survival, with fewer hot flashes and more gynecomastia.

Sources

  1. Bayer HealthCare Pharmaceuticals. Climara (estradiol transdermal system), prescribing information. DailyMed.
  2. Sandoz Inc. Vivelle-Dot (estradiol transdermal system), prescribing information. DailyMed.
  3. Bayer HealthCare Pharmaceuticals. Menostar (estradiol transdermal system), prescribing information. DailyMed.
  4. Ascend Therapeutics US. EstroGel 0.06% (estradiol gel), prescribing information. DailyMed.
  5. Vertical Pharmaceuticals. Divigel (estradiol gel) 0.1%, prescribing information, revised February 2026. DailyMed.
  6. Padagis US. Evamist (estradiol transdermal spray), prescribing information. DailyMed.
  7. US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. February 12, 2026. FDA.
  8. US Food and Drug Administration. FDA update on estradiol transdermal patch availability. September 2026. FDA.
  9. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840–845. PubMed.
  10. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227–1231. PubMed.
  11. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ. 2019;364:k4810. PubMed.
  12. Renoux C, Dell’aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010;340:c2519. PubMed.
  13. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014;161(4):249–260. PubMed.
  14. Langley RE, Kynaston HG, Alhasso AA, et al. A randomised comparison evaluating changes in bone mineral density in advanced prostate cancer: luteinising hormone-releasing hormone agonists versus transdermal oestradiol. Eur Urol. 2016;69(6):1016–1025. PubMed.
  15. Langley RE, Gilbert DC, Duong T, et al. Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme. Lancet. 2021;397(10274):581–591. PubMed.
  16. Langley RE, Gilbert DC, Mangar S, et al. Transdermal estradiol patches in locally advanced prostate cancer. N Engl J Med. 2026;394(16):1595–1607. PubMed.
  17. Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869–3903. PubMed.
  18. Electronic Code of Federal Regulations. 21 CFR 1308.13, Schedule III. eCFR.
  19. World Anti-Doping Agency. The 2026 Prohibited List. WADA 2026 Prohibited List.